Story perspectives

Three-Year-Old Thrives After Groundbreaking Gene Therapy

11/24/2025

Summary

Story summary

Oliver Chu, a three-year-old patient, became the first recipient of a one-time stem cell gene therapy for Hunter syndrome developed over ten years at the University of Manchester in February 2025.
The treatment is a one-time therapy that corrects the faulty gene and enables production of a vital enzyme.
Since receiving the treatment in February 2025, Oliver has shown remarkable recovery and no longer requires weekly enzyme infusions, with Ricky reporting improvements in mobility and cognitive abilities.
Oliver is part of a five-child clinical trial, offering hope that this approach could benefit other genetic conditions.

1 of 1

Story summary

Oliver Chu, a three-year-old patient, became the first recipient of a one-time stem cell gene therapy for Hunter syndrome developed over ten years at the University of Manchester in February 2025.
The treatment is a one-time therapy that corrects the faulty gene and enables production of a vital enzyme.
Since receiving the treatment in February 2025, Oliver has shown remarkable recovery and no longer requires weekly enzyme infusions, with Ricky reporting improvements in mobility and cognitive abilities.
Oliver is part of a five-child clinical trial, offering hope that this approach could benefit other genetic conditions.